Чернобровкин, Г. С., 罗戈津德., & 彼得罗娃阿. (2025). 巨细胞骨肿瘤的恶性转化是对罕见临床病例的综述。. VOPROSY ONKOLOGII, 70(6), 1209–1214. https://doi.org/10.37469/0507-3758-2024-70-6-1209-1214

摘要

骨巨细胞瘤是一种局部侵袭性和很少转移的肿瘤，由外观均匀的肿瘤单核基质细胞和巨噬细胞和破骨细胞样巨细胞混合而成。一小部分病例是恶性的[1]。用denosumab对这种肿瘤进行药物治疗的需求越来越大，因为其优点是不可否认的。例如，它降低了广泛手术干预的可能性，与疼痛综合征严重程度的快速和临床显着降低相关，降低了疾病复发的风险。然而，最近罕见地有骨巨细胞瘤恶性转化治疗地诺单抗的临床病例报道[2]。
我们提出denosumab治疗后GCTB恶性转化的极端罕见病例，在以N.N.Blokhin命名的国家肿瘤学医学研究中心病理学系对其进行了组织学材料的修订。

https://doi.org/10.37469/0507-3758-2024-70-6-1209-1214

##article.numberofdownloads## 12

##article.numberofdownloads## 3

##article.numberofviews## 16

pdf (Русский)

pdf suppl (Русский)

参考

WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer. 2020.

Broehm C.J., Garbrecht E.L., Wood J., Bocklage T. Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep Med. 2015; 2015: 767198.-DOI: https://doi.org/10.1155/2015/767198.

Behjati S., Tarpey P.S., Presneau N., et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45: 1479-1482.-DOI: https://doi.org/10.1038/ng.2814.

Presneau N., Baumhoer D., Behjati S., et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015; 1: 113-123.-DOI: https://doi.org/10.1002/cjp2.13.

Khazaei S., De Jay N., Deshmukh S., et al. H3.3 G34W Promotes growth and impedes differentiation of osteoblast-like mesenchymal progenitors in giant cell tumor of bone. Cancer Discov. 2020; 10(12): 1968-1987.-DOI: https://doi.org/10.1158/2159-8290.CD-20-0461.

Verma V., Puri A., Shah S., et al. Giant cell tumor developing in paget's disease of bone: a case report with review of literature. J Orthop Case Rep. 2016; 6(4): 103-107.-DOI: https://doi.org/10.13107/jocr.2250-0685.594.

Borgers A., Peters S., Sciot R., De Smet L. Giant cell tumor of distal phalanx in an adolescent with Goltz-Gorlin syndrome. Genet Couns. 2014; 25(4): 445-51.

Musharbash F.N., Edelstein A., El Abiad J.M., et al. Risk of malignant transformation of giant cell tumors of bone is 8 times lower with megavoltage vs. orthovoltage radiation therapy. Agarwal M., ed. Sarcoma. 2022; 2022: 1-7.-DOI: https://doi.org/10.1155/2022/7216296.

Mori K., Berreur M., Blanchard F., et al. Receptor activator of nuclear factor-κB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep. 2007; 1365-1371.-DOI: https://doi.org/10.3892/or.18.6.1365.

van Langevelde K., Cleven A.H.G., Navas Cañete A., et al. Malignant transformation of giant cell tumor of bone and the association with denosumab treatment: a radiology and pathology perspective. Sarcoma. 2022; 2022: 3425221.-DOI: https://doi.org/10.1155/2022/3425221.

Hartmann W., Harder D., Baumhoer D. Giant cell-rich tumors of bone. Surg Pathol Clin. 2021; 14(4): 695-706.-DOI: https://doi.org/10.1016/j.path.2021.06.010.

Tariq M.U., Umer M., Khan Z., et al. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists. Ann Diagn Pathol. 2020; 45: 151479.-DOI: https://doi.org/10.1016/j.anndiagpath.2020.151479.

Roitman P.D., Jauk F., Farfalli G.L., et al. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls. Hum Pathol. 2017; 63: 89-97.-DOI: https://doi.org/10.1016/j.humpath.2017.02.008.

Yoshida K.I., Nakano Y., Honda-Kitahara M., et al. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Mod Pathol. 2019; 32(12): 1751-1761.-DOI: https://doi.org/10.1038/s41379-019-0318-5.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.